Literature DB >> 16574721

Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.

S L El Sharkawy1, N F Abbas, M A Badawi, M A El Shaer.   

Abstract

BACKGROUND: Metallothionein is a low-molecular-weight cysteine-rich protein that has the ability to bind and sequestrate heavy metal ions. It is associated with metalloregulatory functions such as cell proliferation, growth and differentiation. AIMS: To investigate the expression of metallothionein in hyperplastic, dysplastic and neoplastic prostatic lesions and to correlate its expression with histological grade of prostatic carcinoma.
METHOD: The study was carried out on formalin-fixed and paraffin-wax-embedded tissue blocks from 8 patients with benign prostatic hyperplasia, 6 patients with prostatic intraepithelial neoplasia (PIN) and 30 patients with prostatic carcinoma, using the streptavidin-biotin technique. The histological grade was defined and the carcinomas were divided into low-grade (Gleason Score 2-4), 12 moderate grade (Gleason Score 5-6) and 10 high-grade (Gleason Score 7-10) carcinomas.
RESULTS: Patchy metallothionein staining of epithelial cells was observed in normal and benign prostatic tissues. All cases of PIN and 20 of 30 patients with prostatic carcinoma showed positive staining for metallothionein. Metallothionein expression considerably increased from low-grade to high-grade tumours. The proportion of cells staining positively for metallothionein was directly correlated with histological grade of prostatic carcinoma. The epithelial cells lack uniformity in staining intensity, but the percentage of strongly positive cells increased with the histological grade of prostatic carcinoma.
CONCLUSIONS: The high incidence of metallothionein expression in PIN in our study suggests that it is associated with early prostate tumorigenesis. Also, metallothionein expression was directly correlated with the histological grade of prostatic carcinoma, suggesting that metallothionein may be a useful marker for predicting the prognosis of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574721      PMCID: PMC1860510          DOI: 10.1136/jcp.2005.033746

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  31 in total

Review 1.  A critical evaluation of the application of biomarkers in epidemiological studies on diet and health.

Authors:  C P Wild; C Andersson; N M O'Brien; L Wilson; J A Woods
Journal:  Br J Nutr       Date:  2001-08       Impact factor: 3.718

2.  Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer.

Authors:  S Somji; M A Sens; D L Lamm; S H Garrett; D A Sens
Journal:  Cancer Detect Prev       Date:  2001

3.  Steroid receptor status, proliferation and metallothionein expression in primary invasive ductal breast cancers.

Authors:  Paweł Surowiak; Piotr Paluchowski; Teresa Wysocka; Andrzej Wojnar; Maciej Zabel
Journal:  Pathol Oncol Res       Date:  2004-12-27       Impact factor: 3.201

4.  Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines.

Authors:  Seshadri Tekur; Shuk-Mei Ho
Journal:  Mol Carcinog       Date:  2002-01       Impact factor: 4.784

5.  Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices.

Authors:  E E Ioachim; A V Charchanti; N E Stavropoulos; E D Athanassiou; M C Michael; N J Agnantis
Journal:  Anticancer Res       Date:  2001 May-Jun       Impact factor: 2.480

6.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

7.  Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.

Authors:  Alfonso Calvo; Nianqing Xiao; Jason Kang; Carolyn J M Best; Isabel Leiva; Michael R Emmert-Buck; Cheryl Jorcyk; Jeffrey E Green
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

8.  Immunocytochemical evaluation of metallothionein (MT) expression in myoepithelial cells of ductal mammary carcinoma and its relation to survival time: analysis of 7-year course of the disease.

Authors:  P Surowiak; P Dziegiel; R Matkowski; J Kornafel; A Wojnar; M Zabe
Journal:  Folia Histochem Cytobiol       Date:  2002       Impact factor: 1.698

9.  Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy.

Authors:  Naing N Lynn; Miles C Howe; Richard J Hale; Gerald N Collins; Patrick H O'Reilly
Journal:  J Urol       Date:  2003-02       Impact factor: 7.450

10.  Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells.

Authors:  Rana Dutta; Donald A Sens; Seema Somji; Mary Ann Sens; Scott H Garrett
Journal:  Prostate       Date:  2002-07-01       Impact factor: 4.104

View more
  3 in total

Review 1.  Metallothionein Lower Under-Expression in Benign Tumors than That in Malignant Tumors: Systematic Review Article and Meta-Analysis.

Authors:  Jie Zhang; Ruijie Sun; Yue Liu; Guinian Wang; Qinglu Wang
Journal:  Iran J Public Health       Date:  2014-06       Impact factor: 1.429

2.  Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.

Authors:  Jaromir Gumulec; Martina Raudenska; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

3.  Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues.

Authors:  Hua Wei; Mohamed Mokhtar Desouki; Shufei Lin; Dakai Xiao; Renty B Franklin; Pei Feng
Journal:  Mol Cancer       Date:  2008-01-21       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.